HIGHLIGHTS
- who: Vol and colleagues from the of Breast Medical Oncology, Unit, The University of Texas MDAnderson Cancer Center, Holcombe Boulevard, Houston, TX, USA have published the research: CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer, in the Journal: (JOURNAL)
- what: To address the potential problem of the characteristics of the validation cohort not sufficiently matching those of this study cohort, the authors examined the predictive performance of a previously developed 30-gene pharmacogenomic predictor of pCR which had also been . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.